Back to top
more

Geron (GERN)

(Real Time Quote from BATS)

$1.52 USD

1.52
1,134,022

-0.01 (-0.65%)

Updated Aug 27, 2026 10:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks

by Zacks Equity Research

Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.

Zacks Equity Research

Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib

by Zacks Equity Research

Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.

Zacks Equity Research

Radius (RDUS) to Stop Work on Abaloparatide Transdermal System

by Zacks Equity Research

Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.

Zacks Equity Research

Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah

by Zacks Equity Research

Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.

Zacks Equity Research

Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC

by Zacks Equity Research

Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.

Zacks Equity Research

Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL

by Zacks Equity Research

Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.

Zacks Equity Research

Regeneron's (REGN) Evkeeza Positive in Late-Stage Study

by Zacks Equity Research

Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.

Zacks Equity Research

Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA

by Zacks Equity Research

Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.

Zacks Equity Research

Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

by Zacks Equity Research

Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

Zacks Equity Research

Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt

by Zacks Equity Research

Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.